Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM)
Brief description of study
The study is designed to rapidly evaluate new therapies to treat the overactive immune response that has been observed in some COVID-19 patients. The study will look at three different study drugs called infliximab (Remicade), abatacept (Orencia), and cenicriviroc (CVC). All three drugs are not approved by the FDA to treat COVID-19 and are considered investigational. This study will compare the effects and safety of remdesivir when used with and without each of the three study drugs.
Clinical Study Identifier: s20-01701
ClinicalTrials.gov Identifier: NCT04593940
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
